Laigo Bio

ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.

uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.

Vertoro transforms woody and agricultural residues into a wide range of bio-based chemicals, materials, and fuels.

Vivici is a B2B ingredients firm that provides nutritious and sustainable animal-free dairy proteins manufactured with precision fermentation to food and beverage manufacturers.

New Dawn Bio is a biotechnology research firm that specializes in wood production.

Triple Bio is a biotech startup focused on improving productivity and sustainability in dairy and beef production using biological and data‑driven technologies.

ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise has created the base for the Trammpolin design and the development towards a prototype.

Detact holds the patent for a new, innovative, real-time, bacterial detection system that enables hospital staff to determine bacterial presence on surface areas with an easy to use system: the b-Swab.

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new preservation solutions and technologies to provide the highest quality of service to organ procurement organizations and transplant centers. The U.S. based company, headquartered in Northbrook, Illinois, is a leading supplier of preservation solutions worldwide with a focus on innovation in organ preservation and machine perfusion. Through a strong focus on collaboration with surgeons and transplant professionals, it continues to explore emerging science and preservation technologies.

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface platforms.

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant challenges of male infertility. We recognize the critical gap in male fertility treatment and are committed to helping people on their path to parenthood. Our innovative in-vitro spermatogenesis (IVS) technology is poised to transform the fertility landscape, offering new hope and innovative solutions to those struggling to conceive. Led by a team of world-renowned scientists and physicians, we are advancing research into clinical applications. Our mission is to make parenthood a reality for more families through ethical, scientifically advanced fertility solutions. Did you know? *1 in 8 couples struggle with infertility. *50% of in vitro fertilization (IVF) procedures fail. *50% of infertility is linked to men. *Male infertility treatment has been stagnant since 1992. Paterna is the first to develop a truly new treatment for male infertility since then. With a strong foundation in science and a commitment to innovation, Paterna BioSciences is uniquely positioned to lead the next generation of male fertility treatments. We are actively seeking funding to accelerate our clinical development and commercialization efforts, bringing our life-changing technology to families worldwide. We help make parenthood possible. Learn more at www.PaternaBio.com Contact us: info@paternabio.com A New Paradigm in Human Reproduction.